We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $43 · 1 analysts
Stored first · Google News · Yahoo Finance (English)
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) ChartMill
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue R&D Push - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue R&D Push The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor Sentiment - Profit Margin Analysis - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor Sentiment - Profit Margin Analysis The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor Sentiment - Margin Compression Risk - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor Sentiment - Margin Compression Risk The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges Higher - EPS Growth Rate - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges Higher - EPS Growth Rate The Legal Advocate
Kyntra Bio CEO Thane Wettig buys $19,852 in stock - Investing.com
Kyntra Bio CEO Thane Wettig buys $19,852 in stock Investing.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | After market close (AMC) | $-3.27 | — | — | $1.22M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $1.15 | — | — | $2.74M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-16.43 | — | — | $26.49M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-12.19 | — | — | $26.36M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 09. 24. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 08. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 49,511 | $335.69M | 0.00% | — | New position |